Skip to main content
. 2023 Jun 9;12(6):1221–1235. doi: 10.21037/tlcr-22-815

Table 2. Correlation of immunohistochemical NHLRC2 expression assessed by image analysis in lung cancer and disease-specific or overall survival.

Lung cancer type NHLRC2 expression 5-year survival (%) P value Mean survival, months (95% CI) Median survival, months (95% CI) P value
Disease specific survival
   Adenocarcinoma Low (n=51) 53.5 0.003 87.41 (68.91–195.90) 80.00 (30.55–129.45) 0.002
High (n=51) 26.7 49.24 (31.97–66.51) 21.00 (15.52–26.48)
   Squamous cell carcinoma Low (n=54) 46.6 0.156 80.53 (60.23–100.83) 46.00 (1.13– 90.87) 0.757
High (n=57) 59.2 73.89 (60.19–87.60) 65.00 (44.30–85.70)
   All Low (n=105) 50.1 0.461 81.71 (67.59–95.83) 70.00 (40.69–99.31) 0.348
High (n=108) 43.8 71.90 (57.59–86.22) 41.00 (20.99–61.01)
Overall survival
   Adenocarcinoma Low (n=51) 49.0 <0.001 74.68 (58.27–91.09) 59.00 (24.83–93.17) 0.001
High (n=51) 21.6 39.31 (25.94–52.67) 18.00 (14.12–21.88)
   Squamous cell carcinoma Low (n=54) 36.9 0.355 65.27 (47.93–82.61) 35.00 (21.80–48.20) 0.590
High (n=57) 43.9 56.52 (45.55–67.48) 55.00 (35.98–74.02)
   All Low (n=105) 43.7 0.127 66.71 (55.15–78.28) 47.00 (27.97–66.03 0.070
High (n=108) 32.4 53.36 (42.93–63.79) 31.00 (21.60–40.40)

CI, confidence interval; n, number; NHLRC2, NHL repeat (named after NCL-1, HT2A and LIN-41)-containing protein 2.

HHS Vulnerability Disclosure